Federal Advocacy

Stay updated on federal initiatives and policies influencing the bio-industry across the country. This category highlights national-level advocacy efforts, initiatives, and developments driving innovation and growth across the industry.

Advocacy Advocacy : Federal Advocacy Advocacy : State Advocacy Association Updates BioConnections® Jobs Event Event : Industry Event Event : MichBio Advocacy Events Event : MichBio Networking Event Event : MichBio Signature Event Event : MichBio Webinar Event : Partner Event Member Feature News News : Industry News News : Member News News : MichBio News/Statement News : Michigan News

Congress passed long-awaited legislation to reauthorize the SBIR and STTR programs, sending the bill to President Trump on April 1, 2026, for...

Read Post

The White House this past week announced a sweeping new tariff policy targeting imported patented pharmaceutical products, positioning the move as...

Read Post

The Trump Administration’s FY2027 budget proposal underscores a significant shift in federal priorities—pairing a record $1.5 trillion...

Read Post

The future of the SBIR/STTR programs has been a critical issue for the life sciences innovation ecosystem, as highlighted in prior biolink...

Read Post

The U.S. drug development landscape is entering a pivotal transition, as federal regulators and research funders accelerate efforts to reduce...

Read Post

A new proposal from the U.S. Environmental Protection Agency (EPA) is reshaping the regulatory landscape for medical device sterilization -...

Read Post

The FDA’s recent draft guidance clarifying the scope of 3-year New Clinical Investigation (NCI) exclusivity is more than a technical update...

Read Post

A bipartisan group of lawmakers has introduced new legislation aimed at tackling a foundational challenge in AI-driven drug discovery - the lack...

Read Post

After months of uncertainty for startups and technology innovators across the country, the U.S. Senate has passed bipartisan legislation, S....

Read Post

The bipartisan House BIOtech Caucus recently announced its first-ever legislative endorsements, backing two bills aimed at strengthening U.S....

Read Post

As Congress considers whether to codify Most Favored Nation (MFN) drug pricing into statute, recent comments by CMS Administrator Dr. Mehmet Oz...

Read Post

The U.S. Food and Drug Administration (FDA) has announced a significant shift in its drug approval standards, moving away from the long-standing...

Read Post